Cold and radiofrequency treatment of lung tumors during a routine bronchoscopy
Tests a cold and radiofrequency device on lung cancer lesions during bronchoscopy.
Plain-language title generated from the registry record
Registry title: Post-Market Registry of Transbronchial Cryo-assisted RFA During Routine Standard Bronchoscopic Tumor Stagng and Resection
Key facts
- Where
- Linz, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a single small lung cancer nodule who are having a routine bronchoscopy and then surgery to remove it. The nodule is treated with a cold and radiofrequency device during the bronchoscopy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- One lung nodule of 2.5 cm (1 in) or smaller, proven to be lung cancer on tissue testing. It must have a margin of at least 20 mm to the pleura, vessels and bronchi.
- Earlier treatment
- People who had SBRT (focused radiation) to the treatment zone, or an investigational therapy in the last 30 days, cannot join.
Main reasons for not taking part
- Pregnant or nursing
- Central tumours touching vital structures
- Electronic implants in the chest
- Blood clotting problem that cannot be corrected, or platelets of 50 × 10⁹/L or lower
- Severe uncontrolled illness or infection
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How old is the patient who may join a trial?
- Is the patient pregnant or breastfeeding?
Source: NCT07530744, who can take part
Where in Austria
- Ordensklinikum Linz ElisabethinenLinz, AustriaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Elisabethinen Hospital
- Trial code
- NCT07530744
- Record updated
- 15 April 2026
- Original description
In order to secure the diagnosis of lung cancer, the investigator will perform a bronchoscopy in order to take tissue samples. These samples will be analyzed in the pathology. This is the routine standard. The aim of the study is to treat the lesion with a device that works both with cold and radiofrequency. The device is already in use for the treatment of lesions. The device allows direct treatment of the lesion during the routine bronchoscopy. As planned, the lesion will then be surgically removed. After the surgery the lesion will be analyzed in the pathology to show the effect of the use of the device. This additional treatment is safe and will support the treatment of the lesion. There are no additional steps or assessments for the participants to undergo.Read full original descriptionShow less
Post-Market Registry of Transbronchial Cryo-assisted RFA During Routine Standard Bronchoscopic Tumor Stagng and Resection
In order to secure the diagnosis of lung cancer, the investigator will perform a bronchoscopy in order to take tissue samples. These samples will be analyzed in the pathology. This is the routine standard. The aim of the study is to treat the lesion with a device that works both with cold and radiofrequency. The device is already in use for the treatment of lesions. The device allows direct treatment of the lesion during the routine bronchoscopy. As planned, the lesion will then be surgically removed. After the surgery the lesion will be analyzed in the pathology to show the effect of the use of the device. This additional treatment is safe and will support the treatment of the lesion. There are no additional steps or assessments for the participants to undergo.
Inclusion: Solitary nodule ≤ 2.5 cm; Candidate for diagnostic bronchoscopy \& LN staging; Eligible for surgical resection; Histologically proven lung cancer; ≥20 mm margin to pleura/vessels/bronchi; Signed informed consent, age ≥18 y.
Exclusion: thoracic electronic implants; severe uncontrolled comorbidities or infection; prior SBRT to zone; recent investigational therapy (<30 d); atelectasis/obstructive pneumonitis/effusion/fibrosis; uncorrectable coagulopathy or platelets ≤50 × 10⁹/L; Pregnancy/nursing; central tumours abutting vital structures; investigator-determined risk.